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ABSTRACT
Nucleophosmin(NPM1)-mutated protein, a leukemia-specific antigen, represents 
an ideal target for AML immunotherapy. We investigated the dynamics of NPM1-
mutated-specific T cells on PB and BM samples, collected from 31 adult NPM1-mutated 
AML patients throughout the disease course, and stimulated with mixtures of 18 
short and long peptides (9-18mers), deriving from the complete C-terminal of the 
NPM1-mutated protein. Two 9-mer peptides, namely LAVEEVSLR and AVEEVSLRK 
(13.9–14.9), were identified as the most immunogenic epitopes. IFNγ-producing 
NPM1-mutated-specific T cells were observed by ELISPOT assay after stimulation with 
peptides 13.9–14.9 in 43/85 (50.6%) PB and 34/80 (42.5%) BM samples. An inverse 
correlation between MRD kinetics and anti-leukemic specific T cells was observed. 
Cytokine Secretion Assays allowed to predominantly and respectively identify Effector 
Memory and Central Memory T cells among IFNγ–producing and IL2–producing T cells. 
Moreover, NPM1-mutated-specific CTLs against primary leukemic blasts or PHA-blasts 
pulsed with different peptide pools could be expanded ex vivo from NPM1-mutated 
AML patients or primed in healthy donors. We describe the spontaneous appearance 
and persistence of NPM1-mutated-specific T cells, which may contribute to the 
maintenance of long-lasting remissions. Future studies are warranted to investigate 
the potential role of both autologous and allogeneic adoptive immunotherapy in 
NPM1-mutated AML patients.
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INTRODUCTION
Nucleophosmin (NPM1) gene mutations, occurring 
in approximately 30% of adult acute myeloid leukemia 
(AML) cases, and in 50–60% of AML cases with a 
normal karyotype, represent one of the most frequent 
molecular lesions observed in AML [1–3]. Moreover, 
NPM1 mutations are specific, being almost exclusively 
restricted to AML, and usually expressed in the entire 
leukemic population [1, 4, 5]. As expected for founder 
genetic lesions, they are also stable throughout the course 
of the disease, with NPM1 mutations almost invariably 
documented in patients experiencing AML relapse [4] 
Most importantly, NPM1 mutations result in structural 
changes of the C-terminus of the NPM1 protein, with 
subsequent aberrant cytoplasmic delocalization, leading 
to perturbations in multiple cellular pathways, critical for 
leukemogenesis [1, 4]. NPM1 cytoplasmic dislocation 
may also favor protein processing and degradation 
pathways, presumably leading to more efficient human 
leukocyte antigen (HLA) presentation [6]. Furthermore, 
none of the normal human sequences present in databanks 
match those of the 11 C-terminal residues of the NPM1 
mutants, suggesting that this aminoacidic sequence may 
serve as a leukemia-specific antigen [6]. Based upon 
the above mentioned biological characteristics, NPM1-
mutated protein may therefore be considered an ideal 
target antigen for AML immunotherapy [7].
Liso et al. previously investigated the ability of 
candidate NPM1-mutated peptides to bind common HLA 
molecules in silico and in vitro. They documented that two 
of the peptides, namely CLAVEEVSL and AIQDLCLAV, 
both deriving from NPM1 mutations A and D, bound to 
HLA-A2 molecules as efficiently as the control peptide 
derived from the Epstein-Barr virus BMLF1 protein [6]. 
Furthermore, Greiner et al. software-screened the entire 
aminoacid sequences of the wild-type and mutated (types 
A, B, C, D) NPM1 protein for HLA-A*0201-binding 
T-cell epitopes [8]. The ten 9-mer peptides with the 
highest predictive scores for HLA binding were evaluated 
in an 8-day culture setting in which peripheral blood (PB) 
CD8+ T cells were stimulated with antigen presenting 
cells (APCs) pulsed with individual peptides, and tested 
for cytokine secretion ability. Two HLA-A2 restricted 
NPM1-mutated peptides, namely #1 AIQDLCLAV and 
#3 AIQDLCVAV, were immunogenic, inducing specific 
T-cell responses in 33% and 44% of NPM1-mutated AML 
patients, respectively. However, only in the case of peptide 
#3 was the frequency of specific responses in NPM1-
mutated AML patients statistically higher than in healthy 
subjects [8]. In addition to these observations, Greiner et al. 
also documented CD8+ T cell cytotoxic activity against 
either peptide-pulsed T2 cells or primary NPM1-mutated 
leukemic blasts [8]. Intriguingly, in a survival analysis of 
25 patients affected with NPM1-mutated AML, a better 
overall survival (OS) was observed in patients with 
NPM1-mutated-specific T-cell responses, suggesting 
that immunity against the mutated region of NPM1 may 
potentially contribute to the favorable clinical outcome of 
NPM1-mutated AML patients [9]. 
In the current study, we performed extensive 
immunological examinations to further identify and 
functionally characterize CD8+ and CD4+ T-cell responses 
directed towards the NPM1-mutated protein in both PB 
and bone marrow (BM) samples collected from 31 adult 
NPM1-mutated AML patients at different time points, 
in order to correlate the dynamics of leukemia-specific 
immune responses with the clinical course of the disease.
RESULTS
Appearance of NPM1-mutated-specific T 
cells in PB and BM of patients with NPM1-
mutated AML and identification of the most 
immunogenic peptides
We performed IFNγ-ELISPOT assays to investigate 
the occurrence of NPM1-mutated-specific T cells in a 
total of 137 PB and 80 BM samples (Table 1), collected at 
different time points, from 31 adults, affected with NPM1-
mutated AML (Figure 1). Overall, NPM1-mutated specific 
immune responses were observed in 26/31 (83.9%) 
patients. In the initial phase of the study, ELISPOT 
assays, carried out after antigenic stimulation with a 
comprehensive mixture containing all of the 18 NPM1-
mutated peptides, documented NPM1-mutated-specific 
T cells producing IFNγ in 34/52 (65.4%) PB samples, 
obtained from the first 17 patients enrolled in the study 
(Figure 1A). Subsequent immunological examinations 
allowed us to identify peptides 13.9 and 14.9 (Figure 2) 
as the most immunogenic 9-mer peptides within the 
C-terminal of NPM1-mutated protein. Indeed, NPM1-
mutated-specific T cells producing IFNγ were found by 
ELISPOT assay after brief ex vivo stimulation with the 
combination of 13.9 and 14.9 peptides, in 43/85 (50.6%) 
PB samples and in 34/80 (42.5%) BM samples, obtained 
from 26 patients of our series (Figure 1B). No differences 
in either percentage of positive samples or magnitude 
of specific immune responses were observed between 
PB samples stimulated with either peptide mixtures. 
Moreover, when results from PB and BM samples were 
compared, no differences were documented (Figure 1B). 
Significantly higher median T-cell responses against 
13.9 and 14.9 NPM1-mutated peptides were observed in 
52 BM samples from 18 patients younger than 60 years, 
compared with those documented in 28 BM samples 
obtained from 8 older patients (p = 0.03, Figure 3A). No 
statistically significant difference was found in younger 
and older patients when PB specific immune responses 
were compared (Supplementary Figure 1A), or when 
immune response to viral antigens, such as CMV, EBV 
and influenza virus, were evaluated in PB or BM (data 
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Table 1: Clinical characteristics of patients with NPM1-mutated acute myeloid leukemia and details on samples 
collected for immunological and molecular monitoring
Number of patients/Sex 31 (16 M/15 F)
Age at AML diagnosis (years), median (range) 56 (19–75)
10/31 (32.3%) patients aged >60 years
PB/BM blasts at diagnosis (%), median (range) 31 (1–90)/60 (20–95)
WBC count at diagnosis (× 109/L), median (range) 23.5 (1.1–260)
Cytogenetics 25 Normal Karyotype (86.2%)
4 Additional Cytogenetic Abnormalities (13.8%)
2 NA (insufficient karyotype analysis)
NPM1 mutation type (n° of patients) A 18/B 3/D 5/others (G, L/Om, ex11, Gm) 4/NA 1
FLT3 mutational status (n° of patients) (%) WT 21 (67.8%)/ITD 5 (16.1%)/TKD 5 (16.1%)
Remission induction chemotherapy regimens* (cases)
Achievement of CR, cases (%)
Consolidation regimens§ (cases)
DAE 19/ “3+7” 8/ MICE 3
27/30 (90%)
cytarabine + daunorubicin 22/ ICE 3/ HDAC 7 
Hematopoietic stem cell transplantation (HSCT), cases (%) autologous HSCT 13 (41.9%)
allogeneic HSCT 5 (16.1%)
autologous and allogeneic HSCT 3 (9.7%)
Leukemia relapses (cases) (%) 16/27 (59.2%)
Follow-up (months), median (range) 30 (8–91)
Alive/ dead patients (cases) (%) 21 (67.7%)/ 10 (32.3%)
IFN-γ ELISPOT assay
n° of analyzed samples (PB/BM)
n° of timepoints per patient (PB/BM), median (range)
n° of patients with samples collected after induction 
chemotherapy
n° of samples collected from 15 patients >12 months after AML 
diagnosis (PB/BM)
n° of PB samples obtained from healthy subjects
217 (137/80)




Cytokine secretion assay (CSA)
n° of analyzed samples (obtained from 18 patients)
PB/BM (n° of samples)
n° of samples per patient (PB/BM), median (range)
33
16 (from 15 patients)/17 (from 12 patients)
1 (1–2)/ 1 (1–3)
MRD monitoring (RQ-PCR mut A, B, D)
n° of analyzed BM samples (obtained from 18 patients)
n° of MRD timepoints per patient, median (range)
102
5 (2–12)
NPM1, nucleophosmin 1; AML, acute myeloid leukemia; PB, peripheral blood; BM, bone marrow; WBC, white blood 
cell; NA, not available; WT, wild type; ITD, internal tandem duplications; TKD, tyrosine kinase domain (D835); IFN-γ 
ELISPOT, interferon-γ Enzyme Linked Immunospot; MRD, minimal residual disease; RQ-PCR, real-time quantitative 
polymerase chain reaction.
*DAE: daunorubicin 50 mg/m2 on days 1, 3, 5, cytarabine 100 mg/m2 on days 1–10, etoposide 50 mg/m2 on days 1–5; 
“3+7” regimen: daunorubicin 45 mg/m2 on days 1–3, cytarabine 100 mg/m2 on days 1–7; MICE: mitoxantrone 7 mg/m2 on 
days 1, 3, 5, cytarabine 100 mg/m2 on days 1–7, etoposide 100 mg/m2 on days 1–3.
One elderly patient from our series received hypomethylating treatment only with 5-azacitidine 75 mg/m2 on days 1–7 
every 4 weeks until progression.
§cytarabine 500 mg/m2 every 12 hours on days 1–6, daunorubicin 50 mg/m2 on days 4–6 for 19 adult patients <60 years; 
daunorubicin 45 mg/m2 on days 1–3, cytarabine 100 mg/m2 on days 1–7 for 3 elderly patients >60 years; ICE, idarubicin  
8 mg/m2 on days 1, 3, 5, cytarabine 100 mg/m2 on days 1–5, etoposide 100 mg/m2 on days 1–3; HDAC, high dose 
cytarabine 3 gr/m2 every 12 hours on days 1, 3, 5.
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not shown). Moreover, we did not document significantly 
different amounts of specific immune responses when 
we compared cases according to FLT3 mutational status 
(Supplementary Figure 1B, 1C). We also analyzed 
specific T-cell responses, according to post-remissional 
therapeutic approaches, comparing samples collected 
after consolidation with chemotherapy only (9 cases), 
autologous hematopoietic stem cell transplantation 
(HSCT) (11 cases) or allogeneic HSCT (6 cases). 
Interestingly, a significantly higher magnitude of immune 
response was found in 11 PB samples obtained after 
allogeneic HSCT, compared with those documented in 37 
PB samples collected after chemotherapy only (p = 0.01) or 
37 PB samples obtained after autologous HSCT (p < 0.05). 
No significant difference was documented between 
responses found after these two latter consolidation 
approaches (Figure 3B). Moreover, no statistically 
significant differences were documented when immune 
responses evaluated in BM samples were stratified 
according to post-remission treatments (Supplementary 
Figure 1D). Intriguingly, after stimulation with the 
combination of 13.9 and 14.9 peptides, IFNγ-producing 
NPM1-mutated-specific T cells (median 70 SFC/106 cells, 
range 68-88) could be revealed by ELISPOT assay in PB 
samples of 3 out of 11 (27.3%) healthy subjects, tested as 
controls.
Correlation between NPM1-mutated-specific 
immune responses, molecular monitoring and 
disease course
IFNγ-producing, specific immune responses were 
documented early in 10 of the 16 (62.5%) patients, 
whose samples were available immediately after having 
achieved morphologic CR with remission induction 
chemotherapy regimens. Furthermore, high frequencies 
of IFNγ-producing NPM1-mutated-specific T cells 
were persistently found in 13 of 15 (86.7%) patients, 
whose PB (52) or BM (28) samples were collected later 
than 12 months after AML diagnosis. Molecular MRD 
monitoring for NPM1-mutated transcripts by RQ-PCR was 
performed on a median of 5 BM samples (range 2–12), 
obtained at different time points from 18 patients with 
an NPM1 gene mutation type A, B, or D. In 12 subjects 
experiencing long-term morphologic CR, for whom BM 
samples were available for molecular analysis, MRD 
was persistently below the cut-off value of 0.1 NPM1-
mutated/ABL1, resulting undetectable in 41 samples (not 
shown). Paradigmatic clinical courses of 16 patients are 
reported in Figure 4. Increased and sustained numbers 
of NPM1-mutated specific T cells were found in patients 
experiencing persistent molecular CR. Conversely, 
either a decreased number or absence of IFNγ-producing 
NPM1-mutated-specific T cells strongly correlated with 
subsequent molecular or morphologic leukemia relapse, as 
observed in patients 4, 15, 19, 20 and 30. Similarly, four 
of the 5 subjects who never exhibited specific immune 
responses against the NPM1-mutated sequence, namely 
patients 5, 21, 23 and 28, experienced AML relapse.
Phenotypic and functional characterization of 
NPM1-mutated–specific T cells
CSA analysis showed the presence of NPM1-
mutated-specific cytokine+ T cells in all of the 33 
analyzed samples, as detailed in Table 1 and Figure 
5A. The analysis of memory T-cell profiles based on 
CD62L/CCR7 expression among NPM1-mutated-
Figure 1: IFNγ-ELISPOT assay to investigate NPM1-mutated-specific T-cell responses. Detection of NPM1-mutated-
specific T cells producing IFNγ in peripheral blood (PB) and bone marrow (BM) samples, collected at different time-points from NPM1-
mutated AML patients, after brief ex vivo stimulation (20 hours) with NPM1-mutated peptides. The ELISPOT assay, carried out after 
stimulation with a mixture containing all 18 NPM1-mutated (9–18 mers) peptides, documented NPM1-mutated-specific T cells in 34/52 
(65.4%) PB samples (median 214 SFC/106 cells, range 63–736) (Panel A). NPM1-mutated-specific T cells were found by ELISPOT assay 
after stimulation with the combination of 13.9 and 14.9 peptides (Panel B), in 43/85 (50.6%) PB samples (median 194 SFC/106 cells, range 
62–696) and in 34/80 (42.5%) BM samples (median 133 SFC/106 cells, range 62–546). Median absolute lymphocyte count observed in the 
analyzed BM samples was 1.9 × 109/L (range 0.2–9.5). Black bars show median values. (P value > 0.05, Mann–Whitney U Test). 
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specific CD8+ and CD4+ T cells is detailed in Figure 5B. 
Briefly, Central Memory (CM) and Effector Memory 
(EM) T-cell phenotypes were equally distributed among 
TNFα–producing T cells, whereas either EM T cells or 
CM T cells, both CD8+ and CD4+, were predominantly 
identified among IFNγ–producing T cells and IL2–
producing T cells, respectively. Of interest, a subset of 
CD107a+ cytotoxic IFNγ-producing T cells was identified 
among both CD8+ (median 12%, range 1-67) and CD4+ 
(median 12%, range 2–49) NPM1-mutated-specific T cells 
(data not shown).
Analysis of cytotoxic activity exerted by NPM1-
mutated-specific T cells
The 13-day cultures of CTLs, stimulated with 
NPM1-mutated antigens and tested for lytic activity, 
included a median 92% (range, 73–98) CD3+ T cells, with 
44% (range, 26–56) CD4+ T cells, with either a naïve or 
CM phenotype (median and range, 48%, 32–69; 22%, 
19–45, respectively), and 30% (range, 16–40) CD8+ T 
cells, with an EMRA phenotype (median and range, 42%, 
28–55). CD3−/CD56+ NK cells and CD3+/CD56+ T cells 
were 6% and 13%, respectively (data not shown).
T cells had a NPM1-mutated–specific lytic activity 
greater than 100 LU10/10
6 in 6 of the 7 subjects tested 
(median lysis against NPM1-mutated-derived peptide-
pulsed targets: 833 LU10/10
6) (Figure 6A). Control 
cultures, stimulated with a mixture of 15-mer peptides 
deriving from viral proteins, did not exhibit lysis greater 
than 50 LU10/10
6 against target cells pulsed with NPM1-
mutated peptides (data not shown). Specific cytotoxicity 
was mediated by both CD8+ and CD4+ T cells in 6 of 7 
subjects, as lysis was observed both with the 5-hr and 12-
hr assay, while in one patient NPM1-mutated-specific lysis 
was exerted exclusively by CD8+ T cells (Figure 6A). 
Figure 2: List of NPM1-mutated-derived peptides. Position and sequences of 18 peptides deriving from the complete C-terminal 
of the NPM1-mutated protein, representative of the most common NPM1 gene mutations, namely A/D, B and C. We designed 15 short (9-, 
11-mers) and 3 long (18-mers) peptides. The different aminoacidic residue specific for each mutation type is marked in bold.
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Among the different NPM1-mutated-peptide mixtures 
employed, the combination of 13.9, 14.9, and 15.11 
peptides (mix 3) was able to elicit specific responses in 
all subjects tested, and results were comparable to those 
observed by using a mix containing all of the peptides 
(mix 4). The combinations of peptides 2.9 and 4.9 (mix 1) 
and 13.9 and 14.9 (mix 2) elicited responses in 4 and 6 
subjects of the 7 tested, respectively, with responses often 
below 100 LU10/10
6 or mediated by a single subpopulation 
of either CD8+ or CD4+ T cells (Figure 6B). We then 
proceeded to assess whether NPM1-mutated-specific 
cytotoxic T cells had the ability to recognize and kill 
leukemia blasts. In 3 of the 4 patients for whom autologous 
AML blasts were available, we could demonstrate a 
strong leukemia-directed lytic activity (median lysis, 
678 LU10/10
6; Figure 6A, 6C). In 3 healthy donors, we 
evaluated the response against HLA-partially matched 
NPM1-mutated-positive AML blasts. A median lysis of 
200 LU10/10
6 (range 66–3000) was observed, which was 
not likely ascribable to alloreactivity, as PHA blasts from 
the same subjects from whom the tested allogeneic blasts 
were isolated were not killed (Figure 6A).
DISCUSSION
In this study, we investigated CD8+ and CD4+ 
T-cell responses directed towards NPM1-mutated 
peptides in NPM1-mutated AML patients. We observed 
the spontaneous emergence of T cells secreting IFNγ 
in response to a 18-peptide pool spanning the complete 
NPM1-mutated protein C-terminal, and identified two 
peptides, 13.9 and 14.9, as the most immunogenic in our 
experimental setting. The 14.9 peptide, known to have 
in silico binding affinity at least for HLA A*02:01, 
A*03:01, A*11:01 and A*68:01, could have a significant 
advantage based on its extreme C-terminal aminoacidic 
sequence, that is shared by the most frequently observed 
NPM1 mutations, namely A/D, B and C. This could 
potentially facilitate documentation of specific immune 
responses, regardless of NPM1 mutation type [6, 8, 
10]. Our ELISPOT assay, performed after brief ex vivo 
antigenic stimulation, differed from the 8-day culture 
ELISPOT analysis utilized by Greiner et al., and this 
difference may account for different aminoacid sequences 
being identified as the most immunogenic [8]. In our 
study, however, the relevance of the identified peptides 
was confirmed in cytotoxicity experiments, performed 
after 13-day in vitro culture. 
In order to expand on the observations by Greiner 
et al. [8, 9], who investigated the presence of NPM1-
mutated-specific T cells in a single PB sample per patient, 
we tested both PB and BM samples, obtained at different 
timepoints, with the aim of studying the dynamics of 
specific immune responses throughout the disease course. 
While the findings did not significantly differ between PB 
and BM samples, robust NPM1-mutated specific T-cell 
responses were identified early after reaching CR by 
remission induction treatments including anthracycline, 
a prototype of immunogenic chemotherapy [11, 12]. 
Sustained specific immune responses were commonly 
observed in patients with long-term CR, whereas either 
decreased number or absence of NPM1-mutated-specific T 
cells strongly correlated with leukemia relapse, suggesting 
an inverse correlation between the kinetics of MRD and 
anti-leukemic specific T cells, as observed in BCR-ABL-
positive acute lymphoblastic leukemia patients [13–15]. 
Figure 3: NPM1-mutated-specific immune responses according to patients’ age and post-remissional treatments. 
Comparison of IFNγ-producing specific T-cell responses against 13.9 and 14.9 NPM1-mutated-derived peptides in BM samples obtained 
from 18 younger (median 140 SFC/106 cells, range 62–546) and 8 older than 60 years patients (median 108 SFC/106 cells, range 80–162) 
(Panel A). In panel B, the comparisons between IFNγ-producing specific immune responses documented on PB samples from 9 patients 
who received chemotherapy only (median 180 SFC/106 cells, range 62–550), and from 11 and 6 patients who underwent either autologous 
(median 180 SFC/106 cells, range 66–696) or allogeneic HSCT (median 468 SFC/106 cells, range 260–672), respectively, are shown. 
Differences observed were statistically significant (*P < 0.05, Mann–Whitney U Test). Black bars show median values.
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The NPM1-mutated-specific immune responses, in some 
cases observed more than 5 years after the completion of 
anti-leukemic treatments, may have a central role in the 
favorable outcome registered in NPM1mut/FLT3-ITDneg 
versus NPM1 non-mutated AML patients. Greiner et al. 
demonstrated a better overall survival in NPM1-mutated 
AML patients with specific CTL responses against 
NPM1-mutated peptides [9]. Indeed, NPM1 mutations 
are generally present on all leukemic blasts, and leukemic 
stem cells from NPM1-mutated AML patients carry 
the mutation [4], thus immune responses directed to 
NPM1mut may contribute to definitive eradication of 
MRD. To further reinforce this hypothesis, Kuzelova et al. 
identified a skewed HLA distribution in AML patients, 
and documented that individuals expressing HLA alleles 
suitable for presenting NPM1-derived peptides should be 
less prone to develop NPM1-mutated AML.10 Indeed, a few 
HLA class I alleles, mainly B*07, B*18 and B*40, showed 
a strikingly reduced incidence in the NPM1-mutated patient 
group compared to healthy controls, as well as with NPM1-
wild type AML patients. Therefore, it has been indirectly 
hypothesized that specific immune responses to the NPM1 
protein may protect a large part of subjects who express 
appropriate HLA alleles from developing AML, and may 
help maintain durable responses in the remaining cases, 
who unfortunately experience AML despite bearing at least 
one of those depleted alleles. In a larger patient cohort, the 
same authors subsequently supported the epidemiological 
hypothesis that anti-NPM1 immune responses could 
contain AML development and contribute to a better 
outcome in NPM1-mutated AML patients who carry 
favorable HLA class I types, such as A*02, B*07, B*40 
and C*07:01 [16].  Finally, Van Der Lee et al. recently 
demonstrated that various NPM1-mutated-derived peptides 
are presented on the surface of primary AML cells and that 
the CLAVEEVSL peptide is a neoantigen which can be 
efficiently targeted by TCR gene transfer in a co-receptor 
independent fashion, resulting in TCR-tranduced cell 
cytolytic capacity against HLA-A*02:01-positive NPM1-
mutated AML cells [17]. Future studies are warranted to 
define a protective anti-leukemic cut-off value, and to 
identify the optimal antigenic burden to mount the highest 
specific anti-leukemic immune response, as previously 
demonstrated in chronic myeloid leukemia [18]. 
NPM1-mutated-specific T-cell responses occurring 
in PB in the allogeneic HSCT setting were significantly 
Figure 4: Correlation between NPM1-mutated-specific T-cell responses and AML course. Immunological monitoring 
of NPM1-mutated-specific immune responses in either PB or BM samples from 16 patients with NPM1-mutated AML and correlation 
with the molecular disease course. Frequencies of IFNγ-secreting NPM1-mutated-specific T cells were assessed at different time-points, 
showing an inverse correlation between NPM1-mutated-reactive T cells and minimal residual disease (MRD) kinetics. Longitudinal data 
tracking MRD kinetics (right, y-axis; black dotted line) and IFNγ-ELISPOT responses observed in PB and BM samples (left, y-axis, blue 
and red continuous lines, respectively) are summarized in a single time-course graph for each patient.
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higher than those observed in patients receiving either 
autologous HSCT or consolidation chemotherapy only. 
These results are not surprising, since 27.3% of healthy 
subjects from our series had IFNγ-producing NPM1-
mutated-specific T-cells, and, in the study by Greiner 
et al., T-cell responses against NPM1-mutated derived 
peptides #1 and #3 were documented in 39% and 18% 
of healthy volunteers, respectively [8]. While it should 
be acknowledged that these results from in vitro assays 
may potentially reflect the general ability of T cells to 
be stimulated by a foreign antigen [10], we have further 
analyzed NPM1-mutated-derived candidate neoepitopes 
with the comprehensive Immune Epitope Database 
(https://www.iedb.org/) [19]. Intriguingly, we found that 
short sequences of four aminoacids from the C-terminal of 
the NPM1-mutated protein, namely LCLA, CLAV, LAVE, 
SLRK and VEEV, are homologous with many common 
bacterial and viral antigens (not shown), suggesting 
possible cross-reactive immune response mechanisms, 
as previously documented in melanoma. [20, 21]. This 
observation may account for the broad immune responses 
observed in our patients, and may also explain the absence 
of a significant difference in the levels of these responses 
in peripheral blood according to age, as the elderly 
patients in our cohort displayed high levels of antiviral 
T-cell responses. 
In a patient with NPM1-mutated AML in molecular 
relapse after allogeneic HSCT, preemptive donor 
lymphocyte infusion (DLI) induced polyspecific CD8+ 
T-cell responses directed also to #1 and #3 NPM1-
mutated peptides, which contributed to molecular CR 
[22]. It was previously described how recipients of 
Figure 5: Characterization of cytokine production and memory T-cell profiles of NPM1-mutated specific T cells by 
cytokine secretion assay (CSA). Frequencies of NPM1-mutated-specific T cells secreting IFNγ, IL2 or TNFα in BM and PB samples, 
collected from a total of 18 patients, are expressed as median percentages of CD8+ T cells (gray columns) or CD4+ T cells (black columns) 
(Panel A). In detail, median frequencies (percentage, range) were as follows: IFNγ–producing CD8+ T cells 0.1% (0.02–0.84), IFNγ–
producing CD4+ T cells 0.11% (0.03–0.51), IL2–producing CD8+ T cells 0.12% (0.01–0.62), IL2–producing CD4+ T cells 0.1% (0.01–
0.52), TNFα–producing CD8+ T cells 0.09% (0.01–0.91), TNFα–producing CD4+ T cells 0.03% (0.01–0.69). In panel B, the memory 
T-cell profiles of NPM1-mutated-specific T cells, collectively found in PB and BM samples, are shown. For each cytokine-secreting 
NPM1-mutated-specific T-cell subset, black portions and light gray portions represent the median percentages of CD4+ effector memory 
(EM) T cells and CD4+ central memory (CM) T cells, respectively, while dark gray portions and white portions represent the median 
percentages of CD8+ EM T cells and CD8+ CM T cells, respectively.
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an allogeneic HSCT who develop extensive chronic 
graft versus host disease are able to generate immune 
responses against wild-type NPM1 [6, 23], while CTL 
lines deriving from colorectal carcinoma patients may 
also recognize NPM1, indicating that this protein is 
immunogenic [24]. Expanding on this observation, 
Kuzelova et al. suggested that the immunogenicity 
of NPM1-mutated protein is presumably favored by 
aberrant cytoplasmic localization and also involves 
several aminoacidic sequences located in the unmutated 
portion of the protein [10]. Despite the observed NPM1-
mutated-specific immune responses in our patients, any 
evidence of epitope spreading to other antigens, present 
on leukemic blasts and potentially inducing T-cell 
responses targeting AML cells, namely WT1, PRAME, 
RHAMM, proteinase 3 or survivin, cannot be excluded 
[7, 15, 25, 26].
As previously reported in a different setting 
[15], by stimulating with dendritic cells pulsed with 
NPM1-mutated peptides that included the 11-mer 
CLAVEEVSLRK peptide along with 13.9 and 14.9 
epitopes, we were able to expand ex vivo leukemia-
specific CD8+ and CD4+ CTLs from AML patients, as 
well as prime leukemia-specific responses in healthy 
donors. The 11-mer peptide allowed for the stimulation 
of CD4+ T cells, that have been shown, in addition to 
providing help to CD8+ CTLs, to mediate potent anti-
tumor, HLA class II-mediated, cytotoxic responses in 
vivo [27]. The bulk CD4+ CTLs in our cultures included 
large numbers of naïve T cells, whose cytolytic activity 
Figure 6: Cytolytic activity exerted by NPM1-specific T cell lines. Cytotoxic activity of PBMCs after 13-day culture in the 
presence of NPM1-mutated–derived peptides against autologous PHA blasts pulsed with NPM1-mutated peptides (Auto NPM1 peptides, 
5 h- and 12 h-cytotoxicity assay), autologous NPM1-mutated blasts (Auto NPM1 blasts, 5 h- and 12 h-cytotoxicity assay), allogeneic 
NPM1-mutated blasts (Allo NPM1 blasts 5 h- and 12 h-cytotoxicity assay), allogeneic PHA blasts from the donor of the allogeneic 
NPM1-mutated blasts (Allo PHA blasts). The results are represented as the number of lytic units per 106 cells (LU10/10
6) and reported 
for each subject tested and as median value. LU values referring to lysis of autologous PHA blasts pulsed with NPM1-mutated peptides 
were calculated after subtraction of background, consisting of cytotoxicity against autologous PHA blasts pulsed with irrelevant peptides 
(Panel A). Cytotoxic responses to NPM1-mutated+ autologous (patients) or allogeneic (donors) leukemic blasts or to NPM1-mutated peptide-
pulsed PHA blasts in the cultures obtained by stimulation with different NPM1-mutated peptide mixtures (mix 1: peptides 2.9 and 4.9; mix 
2: peptides 13.9 and 14.9; mix 3; peptides 13.9, 14.9, and 15.11; mix 4: all 18 peptides) in the subjects tested (Panel B). Boxes indicate 5 
h- and 12 h-cytotoxicity as LU10/10
6, according to color intensity from green (0 LU10/10
6) to bright orange (>999 LU10/10
6), as reported in the 
figure. Nd: not done. Cytotoxicity profile of cultured PBMCs obtained from donor 2 (Panel C). The figure reports the percentage of specific 
lysis against autologous PHA blasts pulsed with NPM1-mutated peptides (dashed line, solid circles) or with control peptides (dashed line, 
open circles), allogeneic NPM1-mutated blasts (solid line, squares), and allogeneic PHA blasts from the same donor of the NPM1-mutated+ 
blasts (dotted line, triangles). The mean percent lysis of duplicate wells for 5 different effector-to-target (E:T) ratios is shown.
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potential was significantly enhanced after CTLA-4 
blockade with checkpoint inhibitors in a mouse model 
of combined immunotherapy for melanoma [27]. 
Indeed, leukemic cells, similar to other cancer cells, 
hijack inhibitory pathways, including activation of 
immune checkpoints, to evade immune recognition and 
destruction by CTLs [25, 28]. Therefore, blockade of 
immune checkpoints has actually emerged as a highly 
promising approach to increase protective anti-tumor 
immunity [28–30]. Greiner et al. recently investigated 
the influence of nivolumab and ipilimumab, agents 
targeting PD-1 and CTLA-4, respectively, on antigen-
specific immune responses against AML blasts in 
functional T-cell assays [31]. Interestingly, the authors 
documented that the addition of nivolumab to CTL 
cultures for several days increased both specific T-cell 
responses against various leukemia-associated antigens, 
mainly PRAME, RHAMM and WT1, as well as T cell 
cytotoxic effects against primary AML blasts [31–33]. 
Furthermore, high PD-L1 expression has recently been 
documented in NPM1-mutated AML cells, especially in 
leukemic progenitor/stem cell compartments, suggesting 
that NPM1-mutated AML patients may potentially be 
candidates for immune checkpoint PD-1/PD-L1-driven 
immunotherapy [34]. 
In conclusion, we observed the spontaneous 
development of specific anti-leukemic T-cell immunity, 
directed against highly immunogenic NPM1-mutated 
peptides in the majority of patients with NPM1-mutated 
AML, which may contribute to the maintenance of 
long-lasting CR [9, 13, 35]. Careful monitoring of the 
correlation between NPM1-mutated MRD transcripts 
and specific T-cell responses against NPM1-mutated 
peptides, easily evaluable in PB samples, could provide 
relevant prognostic information [36–38]. In addition to 
the possibility of generating T cells specifically reactive 
against patients’ primary AML blasts [39, 40]. our data 
also indicated the feasibility of expanding NPM1-
mutated-specific CTL lines from either patients with 
NPM1-mutated AML or healthy donors, who are antigen-
naïve. In this latter instance, “neoantigen-specific DLI” to 
elicit graft-versus-leukemia could be an attractive option 
for NPM1-mutated AML patients, experiencing either 
morphologic or molecular relapse after allogeneic HSCT 
[15, 41–45]. Even though adoptive or vaccine 
immunotherapies are unlikely to be highly effective 
in patients with full-blown leukemia [25, 28], 
these strategies could potentially be of value in 
maintaining CR or, alternatively, eradicating 
persistent MRD, particularly in elderly subjects, 
not eligible for allogeneic HSCT [12, 15, 21]. 
However, prospective studies are warranted to further 
explore the potential clinical role of individualized anti-




We enrolled a cohort of 31 adult patients (median 
age 56 years, range 19–75), affected with NPM1-mutated 
AML, and 11 healthy volunteers. Clinical and biological 
characteristics of the patients are reported in Table 1 and 
Supplementary Tables 1 and 2. All of the enrolled patients, 
except for one elderly subject (Pt 29) who underwent 
hypomethylating treatment with 5-azacitidine, received 
intensive remission induction chemotherapy; morphologic 
complete remission (CR) was achieved in 27/30 (90%) 
of cases. At a median follow-up of 30 months (range 
8–91), 16 of the 27 (59.2%) patients experienced leukemia 
relapse, while, collectively, 21 of 31 (67.7%) patients 
are still alive, in either first or second CR (Table 1 and 
Supplementary Table 1). Written informed consent was 
obtained from the patients and healthy subjects according 
to the Declaration of Helsinki, after obtaining study 
approval by the local Institutional Review Board (Comitato 
Etico Provinciale di Modena–Protocol 4745/13). PB and 
BM samples were longitudinally collected at different 
timepoints, starting from morphologic CR.
NPM1–mutated-derived peptides
NPM1-mutated peptides were synthesized by 
Biosense to a minimum purity of 70% (immunograde 
purity) and confirmed by mass spectrometry. All 18 
peptides (Figure 2) were utilized as leukemia-specific 
antigen stimulation for all immunological assays performed 
in this study, either as mixtures or as individual peptides.
Enzyme-linked immunospot (ELISPOT) assay
The emergence of NPM1-mutated-specific 
interferon-γ (IFN-γ)-secreting T cells was investigated by 
ELISPOT assay, as previously reported [8, 13, 14] and 
detailed in the Supplementary Methods, on 137 peripheral 
blood mononuclear cell (PBMCs) and 80 bone marrow 
mononuclear cell (BMMCs) samples obtained from 
the enrolled patients (Table 1) and 11 PBMC samples 
collected from healthy subjects. A total of 2.5 × 105 cells/
well were stimulated for 20 hours either with different 
mixed pools of NPM1-mutated peptides (each peptide 
used at a final concentration of 50 μg/ml) or with each 
individual peptide. In detail, IFNγ-ELISPOT assay was 
initially performed on 52 PB samples, obtained from 
the first 17 patients enrolled in the study, after antigenic 
stimulation with a comprehensive mixture containing 
all of the 18 NPM1-mutated (9–18 mers) peptides. 
Subsequently, in order to identify the more immunogenic 
peptides, mixtures were progressively split until single 
peptides were individually used as antigenic stimulation 
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for the IFNγ ELISPOT assay on the same samples 
stored from 12 of the 17 patients, previously stimulated 
with the 18-peptide mixture. After having identified 
peptides 13.9 (LAVEEVSLR) and 14.9 (AVEEVSLRK) 
(Figure 2) as the most immunogenic peptides, 14 further 
NPM1-mutated AML patients were enrolled in the study. 
Collectively, 85 PB and 80 BM samples obtained from 
26 patients have been tested by IFNγ ELISPOT assay 
after stimulation with the combination of 13.9 and 14.9 
peptides. Unstimulated PBMCs or BMMCs were used as 
negative controls, whereas anti-CD3 antibody (Mabtech) 
was added to positive control wells [13]. Results were 
considered positive if the number of SFCs/106 cells in 
NPM1-mutated antigen-stimulated wells was 2-fold 
higher than that in control wells, and reached at least 
60 SFCs/106 cells, according to Cancer Immunoguiding 
Program guidelines [46] Mann–Whitney U test or 
Wilcoxon signed rank test were performed to compare 
differences between continuous variables, whereas Chi-
square analysis and the Fisher’s exact test were used for 
categorical variables. A value of p < 0.05 was considered 
statistically significant.
Cytokine secretion assay (CSA)
The functional and phenotypic characterization of 
NPM1-mutated-specific T cells, stimulated for 3 hours 
with the 18 NPM1-mutated peptide mixture, was carried 
out on 33 (16 PB and 17 BM) samples obtained from 
18 patients (Table 1) with the cytokine secretion assay 
(CSA Detection Kit, Miltenyi Biotec, Italy) including the 
following cytokines: IFNγ, interleukin-2 (IL2) and tumor 
necrosis factor-α (TNFα), as previously described [13, 14]. 
The memory phenotype of the cytokine-producing cells 
was assessed after sample counterstaining with mouse 
anti-human monoclonal antibody conjugates, as detailed 
in Supplementary methods. In addition, the cytotoxic 
phenotype of either CD8+ or CD4+ IFNγ-secreting T cells 
was assessed by using a monoclonal antibody against the 
degranulation marker CD107a. Results were expressed as 
CD8+ or CD4+ T cell percentages [13, 14].
Minimal residual disease (MRD) monitoring 
for NPM1-mutated transcripts by reverse-
transcriptase quantitative polymerase chain 
reaction (RQ-PCR)
The levels of NPM1-mutated transcripts were 
analyzed on 102 BM samples collected, at different 
timepoints, from 18 patients (Table 1 and Supplementary 
Table 1) [36, 47–49]. The transcriptional expression 
of NPM1 gene carrying type A, B, or D mutations 
was evaluated using Ipsogen NPM1 mutA, mutB&D 
MutaQuant diagnostic kits (QIAGEN). RQ-PCR positivity 
was defined using a threshold cut-off value of 0.1 NPM1-
mutated/ABL1 [50].
Assessment of NPM1-mutated-specific cytotoxic 
T cells
The presence of specific cytotoxic T-lymphocyte 
(CTL) subsets was evaluated by co-culturing either 
PBMCs or BMMCs from 3 healthy donors or patients’ 
(namely patients 2, 7, 15, 16), obtained from single 
samples resulting positive by the ELISPOT assay, with 
NPM1-mutated peptide-pulsed autologous dendritic 
cells, at a responder/stimulator ratio of 20:1. On day 13, 
responder cells were tested against a panel of targets, 
including autologous mock-pulsed or NPM1-mutated 
peptide-pulsed PHA T-cell blasts (PHA blasts), and 
autologous or allogeneic NPM1-mutated-positive AML 
blasts. PHA blasts were obtained as previously reported.13
Target cells were incubated overnight with 51Cr. 
For the cytotoxicty assay, effector cells were incubated 
with target cells at effector/target (E:T) ratios from 10:1 
to 0.01:1. Results are reported as percent specific lysis at 
different E:T ratios, or as lytic units (LUs) [13].
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